Abstract
Biomarkers are used throughout the drug development process from target identification and validation to post marketing studies. Biomarkers are most impactful in informing dose selection, pathway associated activity and toxicity, clinical efficacy and in identifying subsets of patients who will most likely benefit of a therapy or who will develop a disease-related outcome. Great efforts have been placed in identifying novel biomarkers that may enable drug development. For this, a variety of technologies such as genomics, proteomics, metabolomics, cell-based flow cytometry, etc., are routinely used in the discovery of molecular biomarkers. In this chapter, we discuss the approaches used in discovery of different types of molecular markers and the utilities of these markers to facilitate drug development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Biomarkers and surrogate endpoints (2001) preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95
Laterza OF, Hendrickson RC, Wagner JA (2007) Molecular biomarkers. Drug Inf J 41(5):573–585
van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536
van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009
Hetherington S, Hughes AR, Mosteller M et al (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312):1121–1122
Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4(9):665–676
Laterza OF, Lim L, Garrett-Engele PW et al (2009) Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55(11):1977–1983
Laterza OF, Scott MG, Garrett-Engele PW, Korenblat KM, Lockwood CM (2013) Circulating miR-122 as a potential biomarker of liver disease. Biomark Med 7(2):205–210
Tsongalis GJ, Lockwood CM (2013) Clinical utility of miRNAs in diagnosis and prognosis. Clin Biochem 46(10–11):839
Laterza OF, Modur VR, Crimmins DL et al (2006) Identification of novel brain biomarkers. Clin Chem 52(9):1713–1721
Cox J, Mann M (2011) Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem 80:273–299
Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17(10):994–999
Wiener MC, Sachs JR, Deyanova EG, Yates NA (2004) Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal Chem 76(20):6085–6096
Paweletz CP, Wiener MC, Bondarenko AY et al (2010) Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry. J Proteome Res 9(3):1392–1401
Sanchez-Carbayo M (2011) Antibody microarrays as tools for biomarker discovery. Methods Mol Biol 785:159–182
Pierobon M, Calvert V, Belluco C et al (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 8(2):110–117
Nagele E, Han M, DeMarshall C, Belinka B, Nagele R (2011) Diagnosis of Alzheimer’s disease based on disease-specific autoantibody profiles in human sera. PLoS One 6(8):e23112
Gold L, Ayers D, Bertino J et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12):e15004
Ostroff RM, Bigbee WL, Franklin W et al (2010) Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5(12):e15003
Rhee EP, Gerszten RE (2012) Metabolomics and cardiovascular biomarker discovery. Clin Chem 58(1):139–147
Weiss RH, Kim K (2012) Metabolomics in the study of kidney diseases. Nat Rev Nephrol 8(1):22–33
Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM (2012) Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+T cell phenotypes. Immunity 36(1):142–152
Bendall SC, Nolan GP (2012) From single cells to deep phenotypes in cancer. Nat Biotechnol 30(7):639–647
Wagner JA (2008) Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 48:631–651
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Laterza, O.F., Zhao, X. (2016). Biomarker Discovery. In: Weiner, R., Kelley, M. (eds) Translating Molecular Biomarkers into Clinical Assays . AAPS Advances in the Pharmaceutical Sciences Series, vol 21. Springer, Cham. https://doi.org/10.1007/978-3-319-40793-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-40793-7_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40792-0
Online ISBN: 978-3-319-40793-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)